drugset / Trial / NCT07011849
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with renal cell carcinoma (RCC) and brain metastasis who were previously treated with immune checkpoint blockade.
Timeline
- Start
- 2025-06-04
- Primary completion
- 2025-08-07
- Completion
- 2025-08-07
Outcome
Outcome not reported
Stopped: “0 participants”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |